Immunoglobulin Replacement Therapy in Children

Immunology and Allergy Clinics of North America

Volumn 28, Issue 4, 2008, Pages 833-849

  Garcia Lloret, Maria ^a   McGhee, Sean ^a   Chatila, Talal A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Intravenous immunoglobulin therapy; Primary immunodeficiency diseases; Subcutaneous immunoglobulin therapy

Indexed keywords

ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GLUCOCORTICOID; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; KIOVIG; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANAPHYLAXIS; ASEPTIC MENINGITIS; BACKACHE; BRONCHOSPASM; CATABOLISM; CHILD; CHILDHOOD DISEASE; CHILL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONVULSION; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; FLUSHING; HEADACHE; HEMOLYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; LOADING DRUG DOSE; MALAISE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYALGIA; NAUSEA; NEPHROTIC SYNDROME; NEWBORN; NEWBORN SEPSIS; PRIORITY JOURNAL; PROTEIN LOSING GASTROENTEROPATHY; QUALITY OF LIFE; REVIEW; SEPSIS; SIDE EFFECT; STROKE; SUBSTITUTION THERAPY; THORAX PAIN; THROMBOSIS; TRANSAMINITIS; TREATMENT PLANNING; TREATMENT RESPONSE;

CHILD; DRUG DOSAGE CALCULATIONS; HIV INFECTIONS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT, NEWBORN; INFUSION PUMPS; INJECTIONS, SUBCUTANEOUS; SEPSIS;

EID: 53649092815     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2008.07.001     Document Type: Review

References (100)

1. Jolles S., Sewell W.A., and Misbah S.A. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 142 (2005) 1-11
2. Mahadevia P.J. The pocketbook: pharmacoeconomic issues related to intravenous immunoglobulin therapy. Pharmacotherapy 25 (2005) 94S-100S
3. Nimmerjahn F., and Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26 (2008) 513-533
4. Orange J.S., Hossny E.M., Weiler C.R., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117 (2006) S525-S553
5. Clynes R. Protective mechanisms of IVIG. Curr Opin Immunol 19 (2007) 646-651
6. Givner L.B. Human immunoglobulins for intravenous use: comparison of available preparations for group B streptococcal antibody levels, opsonic activity, and efficacy in animal models. Pediatrics 86 (1990) 955-962
7. Lamari F., Anastassiou E.D., Tsegenidis T., et al. An enzyme immunoassay to determine the levels of specific antibodies toward bacterial surface antigens in human immunoglobulin preparations and blood serum. J Pharm Biomed Anal 20 (1999) 913-920
8. Anonymous. Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting. Bull World Health Organ 60 (1982) 43-47
9. Anonymous. Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives. WHO technical report (1989) Series No 786 Annex
10. Sewell W.A., and Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 107 (2002) 387-393
11. Siegel J. The product: all intravenous immunoglobulins are not equivalent. Pharmacotherapy 25 (2005) 78S-84S
12. Schiff R.I., Williams L.W., Nelson R.P., et al. Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol 17 (1997) 21-28
13. Roifman C.M., Schroeder H., Berger M., et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency: a randomized double-blind trial. Int Immunopharmacol 3 (2003) 1325-1333
14. Rosenfeld E.A., Shulman S.T., Corydon K.E., et al. Comparative safety and efficacy of two immune globulin products in Kawasaki disease. J Pediatr 126 (1995) 1000-1003
15. Cunningham-Rundles C., Zhou Z., Mankarious S., et al. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 13 (1993) 272-278
16. Stiehm E.R. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J 16 (1997) 696-707
17. Agarwal S., and Cunningham-Rundles C. Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol 99 (2007) 281-283
18. Onigbanjo M.T., Orange J.S., Perez E.E., et al. Hypogammaglobulinemia in a pediatric tertiary care setting. Clin Immunol 125 (2007) 52-59
19. Conley M.E., Broides A., Hernandez-Trujillo V., et al. Genetic analysis of patients with defects in early B-cell development. Immunol Rev 203 (2005) 216-234
20. Cunningham-Rundles C., and Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 92 (1999) 34-48
21. Bacchelli C., Buckridge S., Thrasher A.J., et al. Translational mini-review series on immunodeficiency: molecular defects in common variable immunodeficiency. Clin Exp Immunol 149 (2007) 401-409
22. Bonilla F.A., and Geha R.S. Primary immunodeficiency diseases. J Allergy Clin Immunol 111 (2003) S571-S581
23. Buckley R.H. Immunoglobulin G subclass deficiency: fact or fancy?. Curr Allergy Asthma Rep 2 (2002) 356-360
24. Dalal I., Reid B., Nisbet-Brown E., et al. The outcome of patients with hypogammaglobulinemia in infancy and early childhood. J Pediatr 133 (1998) 144-146
25. Moschese V., Graziani S., Avanzini M.A., et al. A prospective study on children with initial diagnosis of transient hypogammaglobulinemia of infancy: results from the Italian primary immunodeficiency network. Int J Immunopathol Pharmacol 21 (2008) 343-352
26. Dorsey M.J., and Orange J.S. Impaired specific antibody response and increased B-cell population in transient hypogammaglobulinemia of infancy. Ann Allergy Asthma Immunol 97 (2006) 590-595
27. Takei S., Arora Y.K., and Walker S.M. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. [see comment]. J Clin Invest 91 (1993) 602-607
28. Driscoll D.J. Long-term results of the Fontan operation. Pediatr Cardiol 28 (2007) 438-442
29. Chehade M., Magid M.S., Mofidi S., et al. Allergic eosinophilic gastroenteritis with protein-losing enteropathy: intestinal pathology, clinical course, and long-term follow-up. J Pediatr Gastroenterol Nutr 42 (2006) 516-521
30. Radhakrishnan K., and Rockson S.G. The clinical spectrum of lymphatic disease. Ann N Y Acad Sci 1131 (2008) 155-184
31. Schnaper H.W. The immune system in minimal change nephrotic syndrome. Pediatr Nephrol 3 (1989) 101-110
32. Kemper M.J., Altrogge H., Ganschow R., et al. Serum levels of immunoglobulins and IgG subclasses in steroid sensitive nephrotic syndrome. Pediatr Nephrol 17 (2002) 413-417
33. Jaffe E., Lejtenyi C., Noya F., et al. Secondary Hypogammaglobulinemia. Immunol Allergy Clin North Am 21 (2001) 141-163
34. Wani M.A., Haynes L.D., Kim J., et al. Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci U S A 103 (2006) 5084-5089
35. Roopenian D.C., and Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7 (2007) 715-725
36. Larsen B., Johnson G., van Loghem E., et al. Immunoglobulin concentration and Gm allotypes in a family with thirty-three cases of myotonic dystrophy. Clin Genet 18 (1980) 13-19
37. Pan Q., and Hammarstrom L. Molecular basis of IgG subclass deficiency. Immunol Rev 178 (2000) 99-110
38. Paris K., and Sorensen R.U. Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immunol 99 (2007) 462-464
39. Alachkar H., Taubenheim N., Haeney M.R., et al. Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immunol 120 (2006) 310-318
40. Carsetti R., Rosado M.M., and Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev 197 (2004) 179-191
41. Holland S.M., DeLeo F.R., Elloumi H.Z., et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 357 (2007) 1608-1619
42. Nichols K.E., Ma C.S., Cannons J.L., et al. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev 203 (2005) 180-199
43. Ochs H.D., Slichter S.J., Harker L.A., et al. The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood 55 (1980) 243-252
44. Spector S.A., Gelber R.D., McGrath N., et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med 331 (1994) 1181-1187
45. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. N Engl J Med 325 (1991) 73-80
46. Grisaru-Soen G., Lau W., Arneson C., et al. Randomized controlled trial of short-term withdrawal of I.V. immunoglobulin therapy for selected children with human immunodeficiency virus infection. Pediatr Int 49 (2007) 972-977
47. Ohlsson A., and Lacy J.B. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev (2004) CD001239
48. Ohlsson A., and Lacy J.B. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev (2004) CD000361
49. Kreymann K.G., de Heer G., Nierhaus A., et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 35 (2007) 2677-2685
50. Laupland K.B., Kirkpatrick A.W., and Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 35 (2007) 2686-2692
51. Trautmann M., Held T.K., Susa M., et al. Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product. Clin Exp Immunol 111 (1998) 81-90
52. Cunningham-Rundles C., Siegal F.P., Smithwick E.M., et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 101 (1984) 435-439
53. Eibl M.M., Cairns L., and Rosen F.S. Safety and efficacy of a monomeric, functionally intact intravenous IgG preparation in patients with primary immunodeficiency syndromes. Clin Immunol Immunopathol 31 (1984) 151-160
54. Nolte M.T., Pirofsky B., Gerritz G.A., et al. Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol 36 (1979) 237-243
55. Liese J.G., Wintergerst U., Tympner K.D., et al. High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child 146 (1992) 335-339
56. Quartier P., Debre M., De Blic J., et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 134 (1999) 589-596
57. Roifman C.M., and Gelfand E.W. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia. Pediatr Infect Dis J 7 (1988) S92-S96
58. Roifman C.M., Levison H., and Gelfand E.W. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1 (1987) 1075-1077
59. Eijkhout H.W., van Der Meer J.W., Kallenberg C.G., et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial. Ann Intern Med 135 (2001) 165-174
60. Schiff R.I., and Rudd C. Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency. J Clin Immunol 6 (1986) 256-264
61. Blaese R.M., Strober W., Levy A.L., et al. Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome: a unique disorder of serum protein metabolism. J Clin Invest 50 (1971) 2331-2338
62. Busse P.J., Razvi S., and Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 109 (2002) 1001-1004
63. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 38 (2007) 122-132
64. Pierce L.R., and Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 17 (2003) 241-251
65. Ahsan N. Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy. J Nephrol 11 (1998) 157-161
66. Burks A.W., Sampson H.A., and Buckley R.H. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia: detection of IgE antibodies to IgA. N Engl J Med 314 (1986) 560-564
67. Hamrock D.J. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 6 (2006) 535-542
68. Sekul E.A., Cupler E.J., and Dalakas M.C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 121 (1994) 259-262
69. Schleis T.G. The process: new methods of purification and viral safety. Pharmacotherapy 25 (2005) 73S-77S
70. Bjoro K., Froland S.S., Yun Z., et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 331 (1994) 1607-1611
71. Abrahamsen T.G., Sandersen H., and Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 98 (1996) 1127-1131
72. Alyanakian M.A., Bernatowska E., Scherrmann J.M., et al. Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes. Vox Sang 84 (2003) 188-192
73. Berger M., Cupps T.R., and Fauci A.S. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 93 (1980) 55-56
74. Bjorkander J., Wadsworth C., and Hanson L.A. 1040 prophylactic infusions with an unmodified intravenous immunoglobulin product causing few side-effects in patients with antibody deficiency syndromes. Infection 13 (1985) 102-110
75. Chapel H.M., Spickett G.P., Ericson D., et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 20 (2000) 94-100
76. Gardulf A., Andersen V., Bjorkander J., et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 345 (1995) 365-369
77. Gardulf A., Nicolay U., Asensio O., et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies: a prospective, multi-national study. J Clin Immunol 26 (2006) 177-185
78. Gaspar J., Gerritsen B., and Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 79 (1998) 48
79. Ochs H.D., Gupta S., Kiessling P., et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 26 (2006) 265-273
80. Remvig L., Andersen V., Hansen N.E., et al. Prophylactic effect of self-administered pump-driven subcutaneous IgG infusion in patients with antibody deficiency: a triple-blind cross-over study comparing P-IgG levels of 3 g l-1 versus 6 g l-1. J Intern Med 229 (1991) 73-77
81. Ugazio A.G., Duse M., Re R., et al. Subcutaneous infusion of gammaglobulins in management of agammaglobulinaemia. Lancet 1 (1982) 226
82. Waniewski J., Gardulf A., and Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 14 (1994) 90-97
83. Gardulf A., Borte M., Ochs H.D., et al. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 126 (2008) 81-88
84. Gardulf A., and Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 6 (2006) 434-442
85. Cottler-Fox M., Lynch M., Pickle L.W., et al. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels. Bone Marrow Transplant 8 (1991) 27-33
86. Leen C.L., Yap P.L., and McClelland D.B. Increase of serum immunoglobulin level into the normal range in primary hypogammaglobulinaemia by dosage individualization of intravenous immunoglobulin. Vox Sang 51 (1986) 278-286
87. Ochs H.D., Fischer S.H., Wedgwood R.J., et al. Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med 76 (1984) 78-82
88. Schleinitz N., Jean E., Benarous L., et al. Subcutaneous immunoglobulin administration: an alternative to intravenous infusion as adjuvant treatment for dermatomyositis?. Clin Rheumatol 27 (2008) 1067-1068
89. Gustafson R., Gardulf A., Hansen S., et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol 152 (2008) 274-279
90. Bjorkander J., Nikoskelainen J., Leibl H., et al. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang 90 (2006) 286-293
91. Church J.A., Leibl H., Stein M.R., et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol 26 (2006) 388-395
92. Fasth A., and Nystrom J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr 96 (2007) 1474-1478
93. Nicolay U., Kiessling P., Berger M., et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 26 (2006) 65-72
94. Berger M., Cupps T.R., and Fauci A.S. High-dose immunoglobulin replacement therapy by slow subcutaneous infusion during pregnancy. JAMA 247 (1982) 2824-2825
95. Gardulf A., Andersson E., Lindqvist M., et al. Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women. J Clin Immunol 21 (2001) 150-154
96. Arora R., Newton T.C., and Nelson M.R. Subcutaneous immunoglobulin therapy in an 11-year-old patient with common variable immunodeficiency and von Willebrand disease. Ann Allergy Asthma Immunol 99 (2007) 367-370
97. de Albuquerque Campos R., Sato M.N., and da Silva Duarte A.J. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol 20 (2000) 77-82
98. Sundin U., Nava S., and Hammarstrom L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 112 (1998) 341-346
99. Quinti I., Soresina A., Agostini C., et al. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration. J Clin Immunol 28 (2008) 263-267
100. Stiehm E.R., Casillas A.M., Finkelstein J.Z., et al. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol 101 (1998) 848-849